Skip to main
BNTX
BNTX logo

BioNTech SE (BNTX) Stock Forecast & Price Target

BioNTech SE (BNTX) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 45%
Buy 27%
Hold 27%
Sell 0%
Strong Sell 0%

Bulls say

BioNTech's financial position is bolstered by a robust liquidity position, ending the third quarter of 2025 with approximately €16.7 billion in cash, cash equivalents, marketable securities, and trade receivables, which provides a strong foundation for continued investment in its extensive oncology pipeline. Positive developments surrounding BNT323, specifically in its Phase 3 DYNASTY-Breast02 trial, suggest potential advancements in targeted cancer therapies that could enhance market competitiveness and revenue streams. Furthermore, the efficacy of its LP.8.1-adapted monovalent COVID-19 vaccine in generating strong immune responses against various SARS-CoV-2 sublineages highlights BioNTech's ongoing relevance in the infectious disease market, complementing its core focus in oncology.

Bears say

BioNTech faces several significant risks that contribute to a negative outlook, including potential negative clinical data across multiple drug candidates, which could hinder the advancement of its oncology pipeline. Additionally, the company reported a net loss per diluted share of €0.12 for the third quarter of 2025, with projections indicating a full-year net loss of €3.99 per diluted share, reflecting ongoing financial challenges. The changing dynamics in the COVID-19 vaccine market, particularly due to stricter regulations in the U.S., may divert investor focus away from BioNTech's core oncology portfolio in the near term.

BioNTech SE (BNTX) has been analyzed by 11 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 27% recommend Buy, 27% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BioNTech SE and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BioNTech SE (BNTX) Forecast

Analysts have given BioNTech SE (BNTX) a Buy based on their latest research and market trends.

According to 11 analysts, BioNTech SE (BNTX) has a Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $137.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $137.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BioNTech SE (BNTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.